Sotagliflozin Reduces Stroke, MI, and CV Death, Regardless of CVD History

April 04, 2022

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

Deepak Bhatt, MD, MPH: Estimating the Potential US Patient Population for Finerenone

April 04, 2022

We sat down with Deepak Bhatt, MD, MPH, at ACC.22 to discuss a study he took part in assessing the potential patient population of finerenone using eligibility criteria from FIDELIO-DKD and FIGARO-DKD against information from NHANES.

ACC, AHA, and HFSA Partner to Release 2022 Heart Failure Guidelines

April 01, 2022

Released on the eve of ACC.22, the 2022 heart failure guidelines represent a collaborative effort by the ACC/AHA/HFSA and include major additions, including a new focus on the use of SGLT2 inhibitors and revisions to the ACC/AHA stages of heart failure.

FDA Issues CRL for Vadadustat in Treatment of Anemia Due to CKD

March 30, 2022

On March 30, Akieba Therapeutics announced the receipt of a CRL from the FDA for their NDA for vadadustat as a treatment for anemia due to chronic kidney dialysis in adult patients on dialysis and not on dialysis.

Don't Miss a Beat: ACC.22 Preview

March 30, 2022

Headed to ACC.22 this weekend or following along virtually? Hear from Don't Miss a Beat co-hosts Drs. Vaduganathan and Greene on their top picks from the late-breaking sessions at the upcoming American College of Cardiology meeting.

Cardiology Month in Review: March 2022

March 26, 2022

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. March's month in review features news on EMPA-KIDNEY, VITAL-AF, COSMOS, and more.